Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor α and not by the FasL-Fas interaction: Effect of pentoxifylline on the development of mucosal atrophy

Gut

Volumn 45, Issue 2, 1999, Pages 229-235

  Stüber, Eckhard ^a   Buschenfeld A ^a   Von Freier, A ^a   Arendt, T ^a   Folsch U R ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Apoptosis; Crypt cell; Fas ligand; Graft versus host disease; Pentoxifylline; Tumour necrosis factor

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PENTOXIFYLLINE; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; CRYPT CELL; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HYPERPLASIA; INTESTINE CRYPT; INTESTINE MUCOSA; INTESTINE VILLUS ATROPHY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032864191     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.45.2.229     Document Type: Article

References (42)

1. Sanders EJ, Wride MA. Programmed cell death in development. Int Rev Cytol 1995;163:105-73.
2. Liebermann DA, Hooffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995;11:199-210.
3. Allen PD, Bustin SA, Macey MG, et al. Programmed cell death (apoptosis) in immunity and haematological neoplasia. Br J Biomed Sci 1993;50:135-49.
4. Stüber E, v Freir A, Marinescu D, et al. Involvement of OX40-OX40L interactions in the intestinal manifestations of murine acute graft-versus-host disease. Gastroenterology 1998;115:1205-15.
5. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 1996;93:2239-44.
6. Garside P, Bunce C, Tomlinson C, et al. Analysis of enterophathy induced by tumour necrosis factor α. Cytokine 1993;5:24-30.
7. Piguet PF, Grau GE, Allet B, et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute graft-vs-host disease. J Exp Med 1987;166:1280-9.
8. Sakai T, Kimura Y, Inagaki-Ohara K, et al. Fas-mediated cytotoxicity by intestinal intraepithelial lymphocytes during acute graft-versus-host disease in mice. Gastroenterology 1997;113:168-74.
9. Zabel P, Schade FU, Schlaak M. Pentoxifyllin eine Syntheschemmer für Tumor-Nekrose-Factor-alpha. Immun Infekt 1992;20:80-3.
10. Guy-Grand D, Vassalli P. Gut injury in mouse graft-versus-host reaction. J Clin Invest 1986;77:1584-95.
11. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
12. Stüber E, Strober W. The T cell-B cell interaction via OX-10-OX40I is necessary for the T cell dependent humoral immune response. J Exp Med 1996;183:979-90.
13. Kayagaki N, Yamaguchi N, Nagao F, et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 1997;94:3914-19.
14. Boussiotis VA, Lee BJ, Freeman GJ, et al. Induction of T cell clonal energy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol 1997;159:3156-67.
15. Stüber ER, Neurath MF, Calderhead D, et al. Crosslinking of OX40-ligand, a member of the NGF/TNF family of cytokine, induces proliferation and differentiation in murine splenic B cells. Immunity 1995;2:507-21.
16. Tsuzuki T, Yoshibai Y, Ito M, et al. Kinetics of intestinal intraepithelial lymphocytes during acute graft-versus-host disease in mice. Eur J Immunol 1994;24:709-15.
17. Potten CS. Regeneration in epithelial proliferative units as exemplified by small intestinal crypts. Ciba Foundation Symposium 1991;161:54-76.
18. Suzuki M, Suzuki Y, Ikeda H, et al. Apoptosis of murine large intestine in acute graft-versus-host disease after allogeneic bone marrow transplantation across minor histocompatibility barriers. Transplantation. 1993;57:1284-7.
19. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. Gastroenterology 1992;102:330-54.
20. Garside P, Reid S, Steel M, et al. Differential cytokine production associated with distinct phases of murine graft-versus-host reaction. Immunology 1994;82;211-14.
21. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13;251-76.
22. Mowat AM. Antibodies to IFN-γ prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989;68:18-23.
23. Williamson E, Garside P, Bradley JA, et al. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmue response and confers long term protection from disease. J Immunol 1997;159:1205-15.
24. Williamson E, Garside P, Bradley JA, et al. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol 1996;157:689-99.
25. Dawoud AA, Nakshabendi I, Foulis A, et al. Immunohistochemical analysis of mucosal gamma-interferon production in coeliac disease. Gut 1992;33:1482-6.
26. Breese FJ, Kumar P, Farthing MJ, et al. Interleukin-2 and interferon-γ producing cells in the lamina propria in coeliac disease. Dig Dis Sci 1994;39:2243.
27. Nilsen EM, Lundin KEA, Krajci P, et al. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon γ. Gut 1995;37:766-76.
28. Przemioslo RT, Lundin KEA, Sollid LM, et al. Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon γ antibody. Gut 1995;36:874-9.
29. Moss SF, Attia, L, Scholes JV, et al. Increased small intestinal apoptosis in coeliac disease. Gut 1996;39:811-17.
30. Guy-Gran D, DiSanto JP, Henchoz P, et al. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-γ, TNF) in the induction of epithelial cell death and renewal. Eur J Immunol 1998;28:730-44.
31. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
32. Bodmer JL, Burns K, Schneider P, et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor I and Fas (Apo-I, CD95). Immunity 1997;6:79-88.
33. Nestel FP, Price KS, Seemayer TA, et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med 1992;175:405-13.
34. Tan X, Hsuch W, Gonzalez-Crussi F. Cellular localization of tumor necrosis factor (TNF)-alpha transcripts in normal bowel and in necrotizing enterocolitis. TNF gene expression by Paneth cells, intestinal eosinophils and macrophages. Am J Pathol 1993;142:1858-65.
35. Keshav S, Lawson L, Chung LP, et al. Tumor necrosis factor mRNA localized to Paneth cells of normal murine intestinal epithelium by in situ hybridization. J Exp Med 1990;171:327-32.
36. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993;23:1745-51.
37. Okuda Y, Sakoda S, Fujimura H, et al. Pentoxifylline delays the onset of experimental allergic encephalomyelitis in mice by modulating cytokine production in peripheral blood mononuclear cells. Immunopharmacology 1996;35:141-8.
38. Wang W, Tam WF, Hughes CCW, et al. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 1997;6:165-74.
39. Tilg H, Eibl B, Pichl M, et al. Immune response modulation by pentoxifylline in vitro. Transplantation 1993;56:196-201.
40. Waage A, Sorensen M, Stordahl B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet 1990;335:543.
41. Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after home marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993;82:732-6.
42. Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993;82:2025-30.